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BACKGROUND: Medication reviews are recommended
annually for older patients. A medication review is a
discussion of a patient’s complete set of medications,
but the actual content of a review is not well specified.
The medical literature suggests that it is an exhaustive
evaluation, but what physicians actually ask about
their patients’ medication regimens has been little
studied.
OBJECTIVE: To describe what physicians do when they
review medications in the office setting.
METHODS: Qualitative content analysis of audio-taped
encounters between 100 patients aged 65 and older and
28 primary care physicians in two health care systems
in Sacramento, California.
RESULTS: Physicians use a combination of non-
mutually exclusive strategies when reviewing chronic
medications that include: (1) efforts to obtain a complete
list of patient medications (36% of visits), (2) discussion
of a topic related to the management of each of a
patient’s chronic medications (47% of visits), and (3)
sequential discussion of the majority of a patient’s
medications without intervening discussion (45% of
visits). Of 10 medication management topics that were
discussed in medication reviews, a mean of 1.5 topics
(SD=1.7, range 0–7) were mentioned for each medica-
tion, with efficacy and directions being most common.
Physicians conducted a sequential discussion that
included discussion of each of a patient’s medications
in only 32% of visits.
CONCLUSIONS: Comprehensive discussions about
chronic medications are uncommon in routine practice.
Practical conceptualization of what constitutes a physi-
cian-conducted medication review is needed.
KEY WORDS: medication review; drug therapy management;
pharmaceutical care; physician-patient communication; qualitative
methods.
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INTRODUCTION
Prescription medication use in the United States is increasing,
with the average person filling over 12 pharmacy prescriptions
per year in 2006.
1 Older patients, who fill a mean of 30
prescriptions each year,
2 are particularly susceptible to med-
ication-related problems associated with polypharmacy and
multiple prescribing physicians.
3 In addition, older patients
frequently take their medications differently from the way they
are prescribed, often take medications of which their physi-
cians are unaware,
4–6 and are commonly nonadherent to their
medication regimens.
7 Some of these discrepancies arise due
to confusion about how to take medications or are related to
patient-experienced adverse effects.
8 Because of this, it is
important for clinicians to conduct medication reviews.
A medication review is a discussion of a patient’s complete
medication list. Studies have found that pharmacist-led
medication reviews can correct some medication-related dis-
crepancies, lower medication costs, and decrease the number
of drugs prescribed.
9–12 However, meta-analyses and system-
atic reviews have found no association between pharmacist-led
medication reviews and lower hospital admission rates or
mortality in older patients,
10,13 perhaps because some
patients prefer physician-led discussions.
14 Physician-con-
ducted medication reviews can result in more appropriate
patient medication use,
15 but clinical outcomes of reviews
have not been studied.
Quality measures and guidelines recommend that physi-
cians conduct medication reviews at least yearly with all older
patients,
16,17 but do not specify the content of these reviews or
the manner in which they should occur. National quality and
safety measures specify that medication reconciliation should
occur after a hospitalization and across the continuum of
care.
18–20 These measures suggest that providers should
obtain a list of all of a patient’s medications, and also review
the medication dose, frequency, route of administration, and
indication for each medicine.
19,21 The pharmacy literature
describes different types of medication review: a prescription
review to address technical issues related to prescriptions, a
concordance and compliance review to address issues related
to patient medication-taking behavior, and a clinical medica-
tion review that addresses medication issues in the context of a
patient’s clinical condition.
22 Comprehensive medication
reviews
9,22,23 may require 30–45 min to complete, and are
infeasible for physicians to perform in busy primary care
settings.
Currently, there are no empirically based recommendations
concerning how physicians should conduct medication
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1296reviews, and few studies have examined how physicians
approach the content of a medication review.
24,25 To compli-
cate the issue, health care providers have mixed opinions
about the purpose of a medication review, which may result in
different ideas about what to do when conducting a review.
Little is known about how physicians solicit information about
chronic medications, what the discussions consist of, and how
they are integrated into an office visit. An understanding of
these strategies could lead to recommendations to optimize
communication. The goal of this study was to describe how
physicians conduct medication reviews when seeing older
patients in the office setting.
METHODS
The investigators analyzed the Physician Patient Communica-
tion Project, a study conducted between January and Novem-
ber 1999 in two health care systems in Sacramento, California.
Patients and physicians were surveyed prior to and immedi-
ately after office visits, and visits were audio-taped and
transcribed. Full study details have been described.
26 The
study was approved by the UC-Davis and UCLA Institutional
Review Boards.
Physician and Patient Samples
Physicians were recruited from the UC-Davis Medical Group
and Kaiser Permanente. Eleven family physicians and 17
internists had patients included in this analysis. Research
assistants randomly sampled physician appointment books
prior to patient visits and telephoned patients aged 18 years or
older. Eligible patients had to speak English and reported
having a new or worsening medical problem, or being at least
“somewhat concerned” about their health or about having a
potentially serious undiagnosed condition.
Of the 4,560 patients selected for contact, 1,332 patients
were eligible for the study, and 909 (68%) were enrolled.
Audiotapes for 632 visits were transcribed. We selected 122
visits in which patients aged 65 and older saw a primary care
provider previously known to them, for either a follow-up visit
(118 encounters) or a comprehensive physical examination (4
encounters). After reviewing the audiotapes and transcrip-
tions, we dropped 7 visits where the tape ended prior to the
end of the visit, 7 where the patient was asked to return to the
office the same day after a diagnostic test, and 8 in which
transcript review and physician report indicated that the
patient was not taking any chronic medications, leaving a
total of 100 visits containing potential medication review
conversations.
Patient and Physician Surveys
Patients were asked about demographics, amount of time
since they last saw any physician, and about their physical
functioning at the time of the visit (36-item Short-Form Health
Survey physical functioning scale, version 1, range from
0–100, with 100 indicating maximum function; α=0.93
27).
Physicians were queried about their demographics and spe-
cialty, and were asked about the number of chronic medica-
tions continued for each patient. We used STATA statistical
software, version 10.0 (StataCorp, College Station, TX) to
tabulate descriptive statistics for patient, physician, visit and
medication characteristics.
Determination of Whether All Chronic Medications
Were Mentioned During Visit
To identify office visits in which each medication was mentioned,
the investigators first reviewed audio tapes and transcripts to
determine the number of chronic medications, vitamins, and
herbal supplements that were mentioned by name, class, or
purpose during the visit. Next, we compared the number of
medications actually mentioned during the visit to the number
of chronic patient medications physicians reported they had the
patient continue on a post-visit questionnaire. If results from
the transcript and survey differed, we used the larger number as
the total number of chronic medications. If the number of
medications discussed during the visit was equal to or greater
than the number reported by the physician, or if the physician
did not respond to the survey question (three visits), we gave
credit for mentioning all patient medications during the visit.
Qualitative Analysis: Approach, Topics,
and Sequential Versus Non-Sequential Discussion
The goals of this analysis were to explore how physicians
approached chronic medication discussions during an office
visit, to determine the topics discussed, and to assess the
sequence in which medications were broached. To do so, the
investigators examined conversations about all chronic pre-
scription medications, vitamins and herbal supplements, over-
the-counter (OTC) and pro re nata (PRN, as needed) medications
that patients were taking at the time of the visit. Conversations
about medications used for acute conditions, such as antibiotics
and cough preparations, were not assessed, nor were new
medication prescriptions, previously discontinued patient med-
ications, or medications discussed but not prescribed.
We employed an iterative qualitative approach to transcript
analysis using a form of qualitative content analysis,
28,29 and
analyzed transcripts inductively using the communication
recorded in the transcripts to understand physician behavior
patterns.
29 The analysis was performed at both the visit and
the medication level. Whether and how physicians introduced
a medication review was explored. For each chronic medication
or supplement mentioned during a visit, the topics brought up
in the conversation concerning the medication were noted.
In addition, we investigated the sequence in which medica-
tions were mentioned during the visit. In “sequential” discus-
sions, medications were mentioned in an uninterrupted
fashion, without intervening non-medication discussion. Non-
sequential medication references occurred when the medica-
tions were mentioned in the context of discussing other care
(e.g., a recent hospitalization or side effect) or when a discus-
sion focused on a single medication. An office visit was defined
as containing a sequential discussion of medications if half or
more of the medications discussed during the visit were
considered in this manner. For patients taking only one
prescription medication, a discussion was considered sequen-
tial if the patient was given the opportunity to list other
medications or supplements, since this could lead to a
sequential discussion of additional medications.
Four investigators participated in the qualitative analysis.
Two of them (DMT, NSW) together identified recurring topics
1297 Tarn et al.: Physician-Conducted Medication Reviews JGIMand developed a system to codify them. A preliminary code-
book was established with topics, definitions, and examples of
each code. A third investigator (SF) reviewed 25% of the
transcripts to help refine the coding system and definitions
and to ensure validity of the codes. Through this process, we
merged and adjusted codes and revised the codebook
accordingly. One of the investigators (DMT) reviewed and
coded all of the transcripts using the final codes, and
another (DAP) double-coded 25% of the transcripts, achiev-
ing a kappa coefficient with omission calculation of 0.86.
30
Disagreements were resolved by consensus among the four
investigators.
RESULTS
The 100 patients in the study had a mean age of 73.6 (SD=5.9,
range 65–89). About half were female, most were Caucasian,
and two-thirds had at least some college education. The mean
number of chronic medications based on physician report was
3.6 (SD=2.8), and the mean number of prescription medica-
tions discussed during the visit was 2.6 (SD=2.1) (Table 1).
Fifteen of the physicians practiced at Kaiser Permanente and
13 at UC-Davis Medical Group. Sixty-eight percent of physi-
cians were male.
Based on transcripts and surveys, the 100 patients were
taking 410 medications. In 54% of visits, a patient’s full set of
medications was mentioned by name, class, or purpose. Of the
410 medications, there were 275 chronic prescription medica-
tions and 54 vitamins or over-the-counter medications. The
other 81 medications cannot be characterized because they
were not explicitly mentioned during the office visit.
Qualitative Analysis
The qualitative analysis revealed two major categories of
discussion about chronic medications. One type of discussion
relates to obtaining a complete list of patient medications. The
second type of discussion is a set of specific topics related to
managing chronic medications. Below we describe these two
major categories. Then we consider the sequence in which
medications are mentioned during visits.
Approach to Obtaining a Patient’s Complete Medication List.
The qualitative analysis identified four types of efforts to
obtain a complete list of patient medications. At least one of
these approaches was found in 36% of office visits. The
approaches consist of: (1) discussion about a patient’s
medication bottles or a patient-generated list of medications,
(2) broad questions assessing patient medications, (3)
questions ensuring that a patient’s entire medication list had
been captured during the visit, and (4) explicit review
(statements in which physicians stated their intention to go
over all of a patient’s medications). Table 2 contains examples
describing each approach.
The following discussions illustrate examples of physi-
cians’ approaches to obtaining a patient’s complete list of
medications. Some physicians asked broad questions that
elicited patient participation in listing their medications, for
example:
Doctor: What medicines are you taking now?
Patient: Okay. I…now I know it is in here someplace.
Okay. I am taking Prilosec at 20 mg one a day, which I
really depend on them things.
Doctor: Um hm.
Patient: And Lipitor, which is for the cholesterol, 20 mg,
one a day. And indocin. Now, indocin I am taking about
one every other day. That is for the gout.
When prompted for his medication list, this patient also
provided additional information, such as the medication dose
and frequency of intake, indicating familiarity with his medi-
cation regimen and the purpose of many of the medicines. In
this example the physician asked a question requiring the
patient to touch on each of her medications, but this did not
always need to occur for a complete assessment of patient
medications. For example, broad questions requiring only a
limited patient response also could give complete information
about medications taken:
Doctor: So you’re not taking anything now?
Patient: That’s right, only the cholesterol, that’s all.
Doctor: Gotcha.
Below is an example of a physician ensuring that a patient’s
complete medication list was captured during the visit. This
physician verified an 82-year-old patient’s medication list with
his daughter by naming the medications and asking for her
agreement about the drugs mentioned:
Doctor: So Lasix, Diovan, Imdur, Cardura. I have Elavil
down. Are you still taking that at bedtime?
Daughter: Uh huh.
Doctor: Okay. So that is five.
Daughter: And Cardizem.
Doctor: Cardizem is six. Potassium is seven. Coumadin
is eight. Are you taking Zantac as well?
Table 1. Patient, Visit, and Medication Characteristics
Characteristic n* Percent
Female 100 53
Caucasian 100 93
Educational level 99
High school or less 32
Some college education 40
College graduate 27
Greater than 2 months since last
visit with any medical doctor
99 33
Visit to a male physician 100 80
Visit to an internist 100 64
UC-Davis patient 100 42
n* Mean (SD) Range
Age 100 73.6 (5.9) 65–89
Physical functioning at time of visit 99 54.0 (25.5) 0–100
No. of chronic meds taken by patient 97 3.6 (2.8) 0–12
No. of prescription meds
discussed during visit
100 2.6 (2.1) 0–8
No. of vitamins/supplements
discussed during visit
100 0.6 (1.3) 0–7
No. of new medications
prescribed during visit
100 0.5 (0.6) 0–3
*Variation in n is due to missing observations
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Doctor: Nine. That sounds about right. Nine pills?
Daughter: Yeah.
Though the patient’s daughter contributed to the conver-
sation by telling the physician about the Cardizem, this type
of query requires little from the patient outside of tacit
agreement.
Another physician, who reported on the physician survey that
his 75-year-old patient was taking five medications, asked a
broad question about whether the patient’s medication list had
recently changed, and followed the question with an explicit
review statement concerning his plans to review the patient’s
medications: Doctor: "Have you started any new medicines
lately?" Patient: "Nope." Doctor: "Because I was going to review
them." Patient: "Same thing. The only one I don’tt a k ea n y m o r e
was that capsule, oh I can’t think of the name now…it’s
brown pills." These types of statements can set the stage for a
complete discussion of a patient’sm e d i c a t i o n s .
Topics Related to Management of Chronic Medications. We
identified ten topics of discussion about specific chronic
medications related to medication management (Table 2): (1)
medication efficacy, (2) directions for use, (3) potential side
effects or adverse events, (4) medication adherence, (5)
laboratory or other monitoring of medications, (6) medication
supply or refills, (7) directions for changing or adjusting
chronic medications, (8) directions for continuing chronic
medications, (9) medication dose, and (10) medication cost or
insurance issues.
Frequency of discussion about each of the topics ranged
from 12% of encounters for cost issues to 66% for efficacy
discussion. In other words, specific medications were most
often discussed in terms of their effect on symptoms or a
disease process. Medication directions were commonly noted
Table 2. Frequency of Discussion and Examples of Approaches to Obtaining a Patient’s Complete Medication List and Topics Related to
Management of Chronic Medications
Approach to obtaining a patient’s complete medication list
*
Percent of encounters
(n=100)
Example
Medication list/bottles 14 “I got these medicines here”
Patient brought medication
bottles/list to visit
Broad question 11 “What medicines are you taking now?”
Physician asked broad question
assessing medications
“You are on basically two medicines?”
“Have you started any new medicines lately?”
Ensure capture 9 “What else are you taking?”
Physician ensured all medications
captured
Explicit review 7 “Let’s review your medicines right now”
Physician stated intention to go
over all medications
Topics related to management of chronic medications
Percent of encounters
(n=100)
Percent of medications
(n=410)
Example
Efficacy 66 31 “…the Tagament seems to be working fine”
“Does that help when you take it?”
“Well, your blood pressure looks really good”
Medication directions 59 27 “You take it three times a day?”
“You only take two at night”
Side effects 37 13 “You see, the blood pressure pill expands my ankles”
“Do you think the Cardizem gives you any side effects?
Does it bother you any?”
“I think part of that is the trazodone. Dry mouth”
Adherence 35 13 “…I haven’t been taking my pills”
“It doesn’t look in the last year like you have gotten
anything filled for cholesterol”
“And you should make sure you take that Fosamax
every day…”
Monitoring 33 12 “Well, we need to check your potassium again”
Medication supply/refills 32 20 “Oh I do need a prescription, before I forget, 90 days
of the Pravachol, 40 mg”
“Do you need any refills on anything?”
Medication changed/adjusted 32 9 “So, stop the Nitro-Bid and a couple of days later
stop the atenolol and see how you do”
Patient told to continue meds 32 17 “Keep all the same medicines going, okay?”
Medication dose 30 10 “That was the 1 mg, right?”
“And the Lotensin 10 mg”
Medication cost/insurance
issues
12 4 MD: “The Xanax is no longer formulary”
Pat: “That doesn’t cost much, but the others are high”
*One or more of these topics were addressed in 36 of 100 encounters
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chronic medications during only eight visits (8%).
Few medication management topics were routinely dis-
cussed during office visits. The mean number of topics (of the
10) discussed during the 100 visits was 3.7 (SD=2.5), with a
range from 0 to 10. In 13% of visits, no medication manage-
ment topic was discussed, and all ten topics were discussed
during only one visit (Fig. 1). One or more medication
management topics were discussed for each of a patient’s
chronic medications in 47% of visits.
Each of the ten medication management topics was dis-
cussed for less than one-third of the 410 medications taken by
the patients in the study (Table 2, column 3). The mean
number of topics discussed for each of the 410 medications
was 1.5 (SD=1.7), with a range of 0 to 7. Prevalence of specific
discussion topics ranged from 4% (cost) to 31% (efficacy)
(Table 2). Forty-two percent of chronic medications had no
medication management topics discussed, 45% had between
one and three topics discussed, and 13% had four or more
topics discussed (Fig. 1).
Patients contributed to the content of the medication
discussions by asking questions or making comments.
Patients brought up medication adherence (particularly pro-
blems with adherence) during 25% of the encounters, while
physicians initiated adherence discussions for 10%. Similarly,
patients brought up medication refills or commented about
their supply of medications more frequently (21% of visits)
than physicians (15% of visits).
Sequential Versus Non-Sequential Discussion. Discussion of
patient medications was not always delimited to a single
conversation. Most frequently medications were mentioned in
a combination of sequential and sporadic discussions
interspersed throughout the office visit. In 45 of the 100
visits, the majority of the patient’s medications discussed
during the visit were reviewed as a sequential discussion in
which medications were mentioned or discussed without
intervening conversation. Medications were more likely to be
mentioned sequentially when physicians made efforts to
obtain a complete list of patient medications (29 of 36 visits;
81%), compared to visits in which no efforts were made (16 of
64 visits; 25%).
Visits in which all of a patient’s medications were explicitly
mentioned by name, medication class, or purpose were more
likely to contain sequential discussion of chronic medications
than those in which not all of a patient’s medications were
named. Among the 54 visits in which all medications were
specifically named, the majority of medications were brought
up sequentially in 32 (59%) visits. In these visits, 167
medications were mentioned (mean 3.1/visit). In contrast, in
the 46 visits in which not all of the chronic medications were
specifically named, the medications were mentioned sequen-
tially in 13 (28%) visits. Only 93 of 243 medications (mean 2.0/
visit) were brought up during these visits with non-sequential
discussions.
Overall Physician Approach to Medication Review
Merging the quantitative with the qualitative findings, in 67 of
the 100 office visits, either each of a patient’s medications was
touched on or the physician attempted to obtain a complete
medication list (but did not specifically name each medication).
Of these 67 visits, sequential discussions occurred in 41 visits
(61%): 32 in which all medications were specifically named,
and 9 in which there was an effort to obtain the patient’s
complete medication list (but not all medications were specif-
ically mentioned). Of these 41 visits, there were 28 in which at
least one medication management topic was raised for each of
the patient’s medications. As a result, a systematic discussion
that touched on at least one topic for each medication the
patient was taking occurred in only 28% of visits.
DISCUSSION
For countless years, physicians have performed the funda-
mental tasks associated with medication review on a daily
basis. Guidelines and quality measures have now canonized
these tasks as required elements of care. This study teases
out what physicians discuss during office visits about a
patient’s medication regimen and shows that most physicians
do not come close to conducting all elements of a medication
review.
Comprehensive evaluation of chronic medications was rare
in the visits studied. Specific details about a medication were
discussed for just over half of the medications the patients
were taking, and none of the 100 continuity office visits in this
study included a comprehensive consideration of dosing,
adherence, efficacy, and side effects.
This analysis identified three distinct aspects of the way that
physicians operationalize medication review during office
visits: efforts aimed at obtaining a patient’s complete medica-
tion list, discussion of topics about medication management,
and sequential versus non-sequential discussion of medica-
tions. These topics are similar to those included in detailed
pharmacist medication reviews,
9,22,23 but are targeted in
clinically relevant ways and often to particular medications or
clinical issues. The elements of physician-conducted medica-
tion review identified in this study may constitute an empiri-
0
5
10
15
20
25
30
35
40
45
10 9 8 7 6 5 4 3 2 1 0
Number of Medication Management Topics
Discussed
% of Visits
% of Meds
Figure 1. Percentage of visits and medications for which topics
related to medication management were discussed.
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review.
Physicians endeavored to conduct a comprehensive ac-
counting of a patient’s medications in several ways. Some were
time-consuming, such as when physicians queried patients
about each of their medications in a systematic fashion.
However, this style may lead to recognition of discrepancies
between what a patient is taking and what the physician
believes the patient is taking. Others, such as asking if any
medications have changed without specifically touching on
each individual medication, could serve to verify a medication
list, but required less participation from the patient. In a
setting in which a patient may have frequent office visits or in
which electronic medical records are accurately maintained,
asking about changes may afford an efficient mechanism for
medication review.
Due to time constraints during office visits, comprehensive
medication review may best be performed by a non-physician
health care provider, such as a nurse or pharmacist. While
pharmacist-led medication-related interventions can improve
patient health outcomes,
31,32 pharmacist medication reviews
in older patients have met with less success.
10,13 Pharmacist
reviews may be limited because they are not directly linked to
changes in clinical care, and physicians do not always
implement pharmacists’ suggestions.
33,34 Older patients may
be reticent to accept pharmacist suggestions
35,36 and may
prefer to have their medications reviewed by their physician.
14
Although not a panacea,
37,38 medication reconciliation fea-
tures incorporated into many electronic health record systems
may allow physicians to implement medication review more
easily.
This study is limited by the nature of the office visits
captured. Few visits were comprehensive examinations, which
we hypothesize would be more likely to contain a medication
review. Physicians may not regularly perform medication
reviews during follow-up visits, and patients may have had
another visit during the year in which their physician
performed a medication review. Physicians who have a reliable
nurse or medical assistant collecting information about patient
medication regimens may not repeat the process. We do not
know whether this occurred prior to the physician-patient
encounter.
This study was also limited because we did not have access
to patient medical records, and instead relied on physician
reports in determining the total number of patient medica-
tions. When the number of medications touched upon during
the visit exceeded the physician’s reported number, we con-
sidered the larger number of medications to reflect the
regimen. This may have resulted in an overestimate of
physician completeness, but does not affect the description of
the topics addressed. Furthermore, we did not require dietary
supplements, over-the-counter, or as needed (PRN) medica-
tions to be assessed, and have no relevant outcome data to
assess the effect of the medication reviews performed. Other
limitations include the potential effect of having a tape recorder
in the room, which may alter physician and patient behavior. If
anything, the Hawthorne effect may have enhanced physician
communication about medications. The patients in this study
were mostly white and well-educated, and most visited a male
physician. In addition, the study focused on older patients in a
single city.
It is increasingly recognized that medication review is a
critical aspect of the clinical encounter. A practical definition of
medication review is needed to monitor performance and guide
interventions. While medication review likely will become more
efficient as physicians adopt electronic medical record sys-
tems, this study illustrates that, at least among the physicians
studied, medication review is not carried out and needs
substantial improvement.
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